{url={type=EXTERNAL, content_id=null, href=}, open_in_new_tab=false, no_follow=false, sponsored=false, user_generated_content=false, rel=}

Tackling CMC Challenges with ARM's Project A-Gene

By Forge Biologics
Jun 30, 2022 5:00:00 PM

Development of Functional 
Potency Assays
A Presentation by Forge Biologics for A-Gene Virtual Workshop Hosted by the Alliance of Regenerative Medicine (ARM)

Forge’s Senior Director of Analytical Development, Adam Davis, Ph.D., and Rebecca Raig, Scientist I, Product Development, discussed best practices for potency assay design and implementation and walked through a case study showcasing how Forge developed an in vitro potency assay for our FBX-101, an AAV gene replacement therapy for the treatment of patients with Krabbe disease.

This webinar was part of ARM's A-Gene Webinar, aimed at tackling the biggest cell and gene CMC challenges.



Adam Davis, Ph.D., Senior Director, Analytical Development


Rebecca Raig, Scientist I, Product Development